Italia markets closed
Dow Jones
36.131,41 +76,98 (+0,21%) Nasdaq
14.340,74 +194,03 (+1,37%) Nikkei 225
32.858,31 -587,59 (-1,76%) EUR/USD
1,0805 +0,0036 (+0,33%) Bitcoin EUR
40.090,00 -705,21 (-1,73%) CMC Crypto 200
893,60 +0,88 (+0,10%)
Dynavax Technologies Corporation (0IDA.L)
LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:07PM GMT
| Chiusura precedente | 13,43 |
| Aperto | 13,37 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 13,34 - 13,50 |
| Intervallo di 52 settimane | 9,50 - 15,15 |
| Volume | |
| Media Volume | 590 |
| Capitalizzazione | 2,826M |
| Beta (5 anni mensile) | 1,35 |
| Rapporto PE (ttm) | 0,18 |
| EPS (ttm) | 0,75 |
| Prossima data utili | 21 feb 2024 - 26 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireClover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements e
© 2023 Yahoo. Tutti i diritti riservati.